To enhance outcomes in both preclinical and clinical tests, the options for mechanism-based (TNF-α, TLRs, and NF-κB) or receptor-focused (such as IL-4R, JAK, and IL-13R) studies to help understand the underlying or fundamental causes of AD must be expanded. This evidence concerns the gene NFKB1 and Alzheimer disease.